ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0794

Peripheral Blood T and B Lymphocyte Subsets in Arthritis in the Elderly

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0619

Pharmacist Intervention: Reducing Insurance Denials of Specialty Medications

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0683

Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0781

Phenotypic and Functional Characterisation of Synovial Fluid-derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0551

Physical Performance as a Mediator of the Association Between Depression and Pain in Knee Osteoarthritis

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0763

Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

9:00AM-11:00AM: Abstract Number: 0659

Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0733

Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0692

Pre-Operative Opioid Usage Increases Length of Stay for Rheumatoid Arthritis Patients Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty

Orthopedics, Low Back Pain, & Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 0717

Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0759

Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Development in a Population at Risk for Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

9:00AM-11:00AM: Abstract Number: 0860

PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0645

Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0905

Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0901

Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].